PATENT CLAIM ANALYSIS

Application Number: 16218287
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "009200"]

Abstract:
The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.

Claim (Index 2):
The method of  claim 1 , wherein the soluble CD52 glycoprotein comprises an amino acid sequence at least 90% identical to the amino acid sequence GQNDTSQTSSPS (SEQ ID NO: 3).

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.45652
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14351501', '15975591', '15384137', '14440703', '14722679']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8162205567816175
- 35 USC 102 Novelty (BERT): 0.6072413006891655
- Combined Prediction Score: 0.7953226311723723
- Mean Citation Score: 580.44497
- Max Citation Score: 668.6121
- Similarity Product: 437.7906628729463

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test